# Effect of GLP-1 Analogue ROSE-010 on Appetite in Overweight and Obese Subjects

> **NCT06621017** · PHASE2 · COMPLETED · sponsor: **Rose Pharma Inc** · enrollment: 40 (actual)

## Conditions studied

- Obesity; Overweight

## Interventions

- **DRUG:** ROSE-010 99 mcg
- **DRUG:** Placebo
- **DRUG:** ROSE-010 150 mcg

## Key facts

- **NCT ID:** NCT06621017
- **Lead sponsor:** Rose Pharma Inc
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2024-09-26
- **Primary completion:** 2025-02-27
- **Final completion:** 2025-02-27
- **Target enrollment:** 40 (ACTUAL)
- **Last updated:** 2025-09-05


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT06621017

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT06621017, "Effect of GLP-1 Analogue ROSE-010 on Appetite in Overweight and Obese Subjects". Retrieved via AI Analytics 2026-06-09 from https://api.ai-analytics.org/clinical/NCT06621017. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*